The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Feasibility and toxicity of neoadjuvant nivolumab with or without ipilimumab prior to extensive (salvage) surgery in patients with advanced head and neck cancer (the IMCISION trial, NCT03003637).
 
Charlotte L. Zuur
Research Funding - Bristol-Myers Squibb (Inst)
 
Joris B. W. Elbers
No Relationships to Disclose
 
Joris L. Vos
No Relationships to Disclose
 
Anne van der Leun
No Relationships to Disclose
 
Xiaohang Qiao
No Relationships to Disclose
 
Baris Karakullukcu
Research Funding - Biolitec Pharma (Inst)
Travel, Accommodations, Expenses - Medtronic
 
Michiel W. M. van den Brekel
No Relationships to Disclose
 
Bing Tan
No Relationships to Disclose
 
Bas Jasperse
No Relationships to Disclose
 
Wouter V. Vogel
Honoraria - Bayer
 
Laura Smit
No Relationships to Disclose
 
Stefan M. Willems
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; MSD; Pfizer; Roche
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; MSD; Pfizer; Roche
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Pfizer (Inst); Roche (Inst)
 
Harm van Tinteren
No Relationships to Disclose
 
Abrahim Al-Mamgani
No Relationships to Disclose
 
Jasper Nijkamp
No Relationships to Disclose
 
Ton N. Schumacher
Employment - Kite, a Gilead company
Stock and Other Ownership Interests - AIMM Therapeutics; Kite, a Gilead company; Neon Therapeutics
Honoraria - AIMM Therapeutics; Neon Therapeutics
Research Funding - Bristol-Myers Squibb; Merck
Patents, Royalties, Other Intellectual Property - -
 
Christian U. Blank
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Lilly (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche/Genentech (Inst)
Research Funding - Bristol-Myers Squibb (Inst); NanoString Technologies (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
J. P. De Boer
No Relationships to Disclose
 
John B. A. G. Haanen
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); MSD Oncology (Inst); Neon Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Research Funding - Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); MSD (Inst)